Biotech's HF Treatment Shows Promise; Phase 3 Study to Launch Next Year
CLEVELAND, Ohio— A potential new treatment for heart failure developed by Cleveland Clinic spinoff Juventas Therapeutics has shown new promise in a Phase 2 trial, according to data recently released by the company. Read the full story.
Leading experts on heart failure care
Our vision is to significantly reduce the burden of heart failure and provide a platform for collaboration, education, innovation, research, and advocacy to improve and expand care.